Cytokinetics Inc to Discuss Positive Topline Results of Redwood-HCM Call Transcript
Good morning, and welcome, ladies and gentlemen, to Cytokinetics conference call announcing the top line results of REDWOOD-HCM. (Operator Instructions) I will now turn the call over to Diane Weiser, Cytokinetics Senior Vice President of Corporate Communications and Investor Relations. Please go ahead.
Welcome, everyone, and thanks for joining us on our call today, which will focus on the top line results of REDWOOD-HCM, the Phase II clinical trial of CK-274, our next-in-class cardiac myosin inhibitor.
Robert Blum, our President and Chief Executive Officer, will begin with an overview of today's announcement. Then Fady Malik, our Executive Vice President of R&D, will present the top line results and our planned next steps in the development program for CK-274. Robert will then provide closing remarks before we open the call to questions.
Please note that portions of the following discussion, including our responses to questions, contain statements that
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |